Exploring the role of intelectin-1 in modulating asthma through the gut-bone-lung axis

探索整合素-1通过肠-骨-肺轴在哮喘调节中的作用

阅读:4

Abstract

BACKGROUND: The development of extra-intestinal diseases is often accompanied by disruptions in intestinal microbiota and its metabolites, yet the mechanistic link between the gut microbiota and asthma remains unclear. We investigated whether intelectin-1 (ITLN1) mitigates allergic asthma through the gut‒bone‒lung axis as a regulator of gut microbial homeostasis. METHODS: Serum samples from 53 asthmatic patients and 34 healthy subjects were analyzed to assess the association between asthma and ITLN1 levels. Mechanism studies were conducted using a house dust mite (HDM)-induced asthma model in Itln1-knockout and Itln1-overexpression mice. Fecal samples were subjected to 16S rRNA sequencing, while lung tissues were analyzed using metabolomics and mRNA sequencing. Butyrate and CCL8-neutralizing antibody were used in the intervention studies, and human serum CCL8 levels were evaluated for clinical relevance. RESULTS: Serum ITLN1 levels inversely correlated with blood eosinophils in asthmatic patients. Itln1 deficiency exacerbated HDM-induced allergic lung inflammation, particularly type 2 inflammation, while Itln1 overexpression attenuated these effects. Fecal 16S rRNA analysis revealed reduced levels of Bifidobacteriaceae, Erysipelotrichaceae, and Muribaculaceae in Itln1-deficient asthmatic mice, mainly due to the loss of agglutination effects of ITLN1. Moreover, Itln1 deficiency correlated with decreased lung butyrate levels, further enhanced macrophage-derived CCL8 production using the NF-κB pathway and then activated CCR3 expression in CD4(+) T cells from bone marrow. Noteworthily, butyrate supplementation or CCL8 neutralization effectively attenuated type 2 inflammation, especially in Itln1 deficiency condition. Additionally, human serum CCL8 levels exhibited a negative correlation with FEV(1)/FVC, FEV(1), and FVC and a positive correlation with neutrophils under asthmatic conditions. CONCLUSION: ITLN1 is a promising therapeutic target linking gut microbial metabolism to asthma immune regulation using the gut‒bone‒lung axis.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。